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Abstract
Background: Pneumocystis pneumonia (PCP) remains a leading cause of morbidity and mortality
in HIV-infected persons. Epidemiology of PCP in the recent era of highly active antiretroviral
therapy (HAART) is not well known and the impact of HAART on outcome of PCP has been
debated.
Aim: To determine the epidemiology of PCP in HIV-infected patients and examine the impact of
HAART on PCP outcome.
Methods: We performed a retrospective cohort study of 262 patients diagnosed with PCP
between January 2000 and December 2003 at a county hospital at an academic medical center.
Death while in the hospital was the main outcome measure. Multivariate modeling was performed
to determine predictors of mortality.
Results: Overall hospital mortality was 11.6%. Mortality in patients requiring intensive care was
29.0%. The need for mechanical ventilation, development of a pneumothorax, and low serum
albumin were independent predictors of increased mortality. One hundred and seven patients
received HAART before hospitalization and 16 patients were started on HAART while in the
hospital. HAART use either before or during hospitalization was not associated with mortality.
Conclusion: Overall hospital mortality and mortality predictors are similar to those reported
earlier in the HAART era. PCP diagnoses in HAART users likely represented failing HAART
regimens or non-compliance with HAART.
Background
The introduction of highly active antiretroviral therapy
(HAART) led to dramatic declines in morbidity and mor-
tality of HIV-infected patients [1,2]. Although a marked
reduction in Pneumocystis pneumonia (PCP) was docu-
mented in the HAART era, PCP remains the leading AIDS-
defining opportunistic infection in the United States [3-
6]. Mortality from PCP has changed multiple times during
the AIDS epidemic with the latest mortality of hospital-
ized patients with PCP reported to be 11% in the early
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ies performed shortly after the introduction of HAART
showed a mortality ranging from 53 to 62% [8-10]. Cer-
tain clinical factors such as low serum albumin, need for
mechanical ventilation, and development of a pneumot-
horax were predictive of mortality [9,11-15]. HAART has
now been widely available for approximately twelve years.
Whether the epidemiology of PCP or predictors of out-
come of HIV-infected patients with PCP have changed in
the recent HAART era is unknown.
The relationship of HAART use to outcome of PCP is also
not well-defined. A previous study found that intensive
care unit (ICU) patients receiving HAART during hospital-
ization had improved mortality [9]. This study was per-
formed early in the HAART era and examined a small
number of patients who were admitted to intensive care.
A more recent study found that PCP patients admitted to
the ICU after mid-1996 had improved outcomes com-
pared to those admitted before the widespread availability
of HAART, independent of HAART use [15]. Other studies
have not found an association of HAART use and outcome
in HIV-infected ICU patients with a variety of diagnoses,
but no studies have examined HAART in non-ICU
patients with PCP. The exact relationship of HAART and
outcome in PCP is unknown and is important for guiding
care of these patients.
We studied patients with PCP at Los Angeles County-Uni-
versity of Southern California (LAC-USC) hospital from
2000 to 2003 to determine the epidemiology of PCP and
investigate the association of HAART and mortality.
Methods
Subjects
Subjects were HIV-infected adults who were discharged
from or died in LAC-USC with a diagnosis of PCP between
January 1, 2000 and December 31, 2003. We conducted a
computerized hospital records search using ICD-9 codes
to identify those patients with either a microscopically-
confirmed or an empiric diagnosis of PCP. Repeat admis-
sions occurring more than two weeks after hospital dis-
charge were considered as separate admissions.
Readmissions within two weeks of discharge were consid-
ered as single admissions. The University of Southern Cal-
ifornia Institutional Review Board approved the study.
Data collection
Data were collected by standardized chart review using
pre-determined definitions and included demographic
information, medical history, laboratory data, and medi-
cation use. A PCP diagnosis was considered definitive if
organisms were visualized on either induced sputum or
bronchoscopic samples. A diagnosis was considered
empiric if subjects presented with a compatible clinical
course, were treated for PCP, and received a discharge
diagnosis of PCP. The development of complications
including pneumothorax and need for ICU admission or
mechanical ventilation (data on non-invasive modes of
ventilation were not available) was recorded. HAART was
defined as the use of at least three drugs from at least two
classes. Details of HAART use included both pre-admis-
sion treatment and initiation or continuation of HAART
during hospital admission. Number of days a patient
received HAART while in the hospital and missed doses
were also noted. In-hospital mortality was the primary
outcome measure.
Statistical analysis
Stata 9.0 (College Station, Texas) was used for all analyses,
and statistical significance determined for a p-value of ≤
0.05. Demographic and clinical data were described using
mean and standard deviation or median and range
depending on normality of the data. Dichotomous varia-
bles were described using percentages. Plasma HIV RNA
viral level values were log-transformed. Analyses includ-
ing CD4 cell counts and HIV RNA viral levels were limited
to patients who had values available within six months of
admission. Clinical characteristics of subjects were com-
pared according to HAART use. Univariate analyses were
performed to determine predictors of mortality. For con-
tinuous variables, either Wilcoxon rank sum or Student's
t-test was used to compare groups. Differences in categor-
ical variables for survivors and non-survivors were
assessed using the chi-square test or Fisher's exact and p-
values adjusted for multiple comparisons as appropriate.
These analyses were repeated for subjects with a definitive
diagnosis of PCP and those with an empiric diagnosis.
Stepwise forward and backward multivariate logistic
regression was performed to determine variables predic-
tive of in-hospital mortality. The robust standard errors
method was used to account for repeat admissions. Varia-
bles were included in the model if they reached a signifi-
cance level of p < 0.1 in univariate analysis. Univariate
predictors were similar for both definitive and empiric
PCP diagnoses; therefore, these groups were combined in
multivariate analyses to improve power. Because we were
specifically interested in the effect of HAART use, we per-
formed several Cox proportional hazard models adjusting
for relevant variables examining differing aspects of
HAART use and impact on survival time.
Results
Demographics and clinical characteristics
284 HIV-infected adults had 355 admissions for PCP at
LAC-USC during the study period. A total of 292 admis-
sions for 262 patients were available for review. Clinical
data for the remaining 63 admissions were unavailable
due to random loss in medical records. Analyses were
repeated including only initial PCP admissions andPage 2 of 10
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hospitalized for PCP and number of patients with PCP
admitted to the ICU over the course of the study are
shown in Figure 1.
Clinical characteristics of subjects are shown in Table 1.
Median age of the subjects was 40 years (range 23 to 68).
The majority (n = 246, 84.2%) were males, and most sub-
jects were Hispanic/Latino (n = 151, 51.7%). Approxi-
mately 60% had a previous diagnosis of AIDS based either
on an opportunistic infection or a CD4 cell count below
200 cells/μl. Sixty-eight (27.6%) had a history of pneumo-
nia other than PCP with 19.1% of these subjects reporting
previous bacterial pneumonia and 55.9% reporting previ-
ous tuberculosis. Almost one quarter (n = 72, 24.7%) had
a past history of PCP, and only 31.5% (n = 92) were using
PCP prophylaxis. Of the patients not reporting use of PCP
prophylaxis, 70 (35.0%) should have been receiving
prophylaxis based on a CD4 cell count below 200 cells/μl
and known HIV status. The remaining patients either had
a CD4 cell count above 200 cells/μl or did not know that
they were HIV-infected. Only one patient had an undetec-
table plasma HIV viral level (less than 50 copies/ml).
Two hundred and forty-five subjects (83.9%) were ini-
tially treated with trimethoprim/sulfamethoxazole (TMP/
SMX). Approximately five percent (n = 14) had a change
in PCP regimen. Reasons noted for treatment change were
development of adverse effects (n = 9, 64.3%) or treat-
ment failure (n = 3, 21.4%). Treatment decisions and dos-
ing regimens were not standardized and were based on
physician preference. The majority of subjects (n = 209,
71.6%) received steroids. Of those with arterial blood gas
data available, 84.7% of patients meeting clinical criteria
received steroids. There was no association of mortality
with appropriate steroid use, likely because there were a
small number of patients who did not receive steroids
when indicated.
One hundred and twenty seven (43.5%) diagnoses were
made empirically based on clinical presentation and
response to anti-Pneumocystis treatment. Patients who had
an empiric diagnosis differed from those in whom a defin-
itive diagnosis was pursued (Table 2). Black subjects were
more likely to be treated empirically than other groups
(odds ratio [OR] = 2.6, 95%CI [confidence interval] =
1.60–4.30, p < 0.001). Empirically-diagnosed patients
were more likely to have known HIV on admission (OR =
1.89, 95%CI = 1.10–3.25, p = 0.02), to have a history of
PCP (OR = 1.80, 95%CI = 1.03–3.07, p = 0.04), and to be
using HAART (OR = 1.8, 95%CI = 1.11–2.92, p = 0.02).
Patients who were empirically diagnosed also tended to
be less severely ill with less frequent ICU admissions (OR
= 0.42, 95%CI = 0.25–0.71, p = 0.001), reduced need for
mechanical ventilation (OR = 0.40, 95%CI = 0.19–0.86, p
= 0.02), fewer pneumothoraces (OR = 0.13, 95%CI =
0.03–0.57, p = 0.002), and lower mortality (6.3% versus
15.8%, OR = 0.36, 95%CI = 0.16–0.82, p = 0.02). They
were also less likely to have PCP therapy changed (OR =
0.09, 95%CI = 0.012–0.72, p = 0.005). In multivariate
modeling, being black was the only independent predic-
tor of an empiric diagnosis (OR = 2.4, 95%CI = 1.40–
4.13, p = 0.001).
Predictors of mortality
Thirty-four patients (11.6%) died during hospitalization.
ICU mortality was 29.0%. Univariate analyses to deter-
mine clinical variables associated with increased in-hospi-
tal mortality found that the need for mechanical
ventilation (OR = 18.0, 95%CI = 7.9–41.1, p < 0.001),
development of a pneumothorax (OR = 10.3, 95%CI =
3.9–27.3, p < 0.001), high serum lactate dehydrogenase
(LDH)(OR = 1.3, 95%CI = 1.09–1.65, p = 0.005), and
high alveolar-arterial oxygen gradient (OR = 1.08, 95%CI
= 1.03–1.12, p = 0.001) predicted increased mortality
(Table 3). High serum albumin (OR = 0.32, 95%CI =
0.17–0.60, p < 0.001) and an empiric diagnosis (OR =
0.36, 95%CI = 0.16–0.82, p = 0.02) were associated with
decreased mortality. Other variables such as age or log-
transformed age, history of PCP, CD4 cell count, HIV viral
RNA levels, change in PCP treatment, and respiratory fail-
ure more than five days after hospital admission were not
associated with mortality. Separate univariate analyses
were performed for the definitive and empiric diagnoses
groups and results were similar (Table 3). In addition,
when empiric diagnosis was included in multivariate
modeling of mortality adjusted for severity of illness, it
did not have an independent association with mortality.
Therefore, multivariate modeling was performed for all
subjects and demonstrated that development of a pneu-
Number of cases of Pneumocystis pneumonia admit-
ted to Los Angeles County-University of Southern 
California hospital and number of cases requiring 
intensive care unit (ICU) admission by year
Figure 1
Number of cases of Pneumocystis pneumonia admit-
ted to Los Angeles County-University of Southern 
California hospital and number of cases requiring 
intensive care unit (ICU) admission by year.Page 3 of 10
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need for mechanical ventilation (OR = 14.8 95%CI = 5.7–
38.9, p < 0.001) were independent predictors of increased
mortality (Table 3). Increasing serum albumin was inde-
pendently associated with increased survival (OR = 0.27
per 0.1 g/dl increase, 95%CI = 0.12–0.61, p = 0.002).
Alveolar-arterial oxygen gradient was available for only
129 subjects and was therefore not included in multivari-
ate modeling as its inclusion decreased the power of the
model.
Table 1: Characteristics of HIV-infected patients with Pneumocystis pneumonia according to HAART status on admission.
Characteristic All (n = 292) Not on HAART (n = 178) On HAART (n = 107)
Age, median years, (range) 40 (23–68) 40 (23–63) 41 (21–68)
Gender, n (%)
Male 246 (84.2) 152 (85.4) 90 (84.1)
Female 46 (15.8) 26 (14.6) 17 (15.9)
Race/ethnicity, n (%)
White 30 (10.3) 17 (9.6) 12 (11.2)
Black 102 (34.9) 63 (35.4) 37 (34.6)
Hispanic/Latino 151 (51.7) 91 (51.1) 57 (53.3)
Other/unknown 9 (3.1) 7 (3.9) 1 (0.9)
HIV risk factor, n (%)
Men who have sex with men 97 (33.2) 58 (32.6) 38 (35.5)
Intravenous drug use 32 (11.0) 18 (10.1) 13 (12.1)
Heterosexual 80 (27.4) 50 (28.1) 29 (27.1)
Blood transfusion 3 (1.0) 1 (0.6) 2 (1.9)
Unknown 80 (27.4) 51 (28.7) 25 (23.4)
Medical history, n (%)
Initial HIV diagnosis 80 (27.4) 79 (44.4) 0 (0)*
History of PCP 72 (24.7) 26 (14.6) 43 (40.2)*
Use of PCP prophylaxis 92 (31.5) 30 (16.9) 60 (56.1)*
Use of HAART 107 (36.6) 0 (0) 107 (100)*
Current smoker 116 (39.7) 74 (41.6) 41 (38.3)
Laboratory values
CD4, cells/μl, median (range)(n = 131) 19 (0–697) 18 (1–267) 22 (0–697)
HIV viral level, log copies/ml, median (range)(n = 57) 5.3 (1.7–5.9) 5.3 (1.7–5.9) 5.3 (2.6–5.9)
Albumin, g/dl, median (range) 2.5 (0.6–4.1) 2.5 (0.6–3.8) 2.4 (0.6–4.1)
LDH, U/l, median (range) 332 (119–1425) 331 (119–1425) 323 (119–962)
Alveolar-arterial oxygen gradient, mm Hg, median (range)(n = 129) 43.3 (18.0–89.0) 44.6 (18.0–89.0) 38.5 (21.8–73.0)
Complications, n (%)
ICU admission 100 (34.2) 66 (37.1) 29 (27.1)
Mechanical ventilation 39 (13.4) 25 (14.0) 11 (10.3)
Pneumothorax 20 (6.8) 17 (9.6) 2 (1.9)^
Respiratory failure after 5 days 10 (3.4) 8 (4.5) 2 (1.9)
Change of PCP therapy 14 (4.8) 10 (5.6) 4 (3.7)
Outcome
Died in-hospital 34 (11.6) 21 (11.8) 10 (9.3)
Length of stay, median days (range) 8 (1–89) 9 (1–89) 6 (2–69)*
Abbreviations: HAART, highly active antiretroviral therapy; ICU, intensive care unit; LDH, lactate dehydrogenase; PCP, Pneumocystis pneumonia.
Note: HAART use was unavailable for 7 subjects.
*p ≤ 0.001
^p = 0.01Page 4 of 10
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One hundred and seven patients (36.6%) received
HAART prior to hospital admission. Duration of HAART
use was available in 35 subjects (32.7%). Of those with a
known duration, 51.4% had started HAART within one
month of admission and 11.4% had started it within one
to six months. Subjects receiving HAART prior to admis-
sion were similar to those not receiving HAART in age,
gender, race/ethnicity, and HIV risk factor (Table 1). More
subjects receiving HAART had a prior history of PCP
(40.2% versus 14.6%, OR = 4.5, 95%CI = 2.50–7.97, p <
0.001) and were using PCP prophylaxis (56.1% vs.
Table 2: Characteristics of HIV-infected patients with empiric compared to definitive diagnoses of Pneumocystis pneumonia.
Characteristic Empiric n = 127 Definitive n = 165 p-value
Age, median years, (range) 41 (23–68) 40 (24–60) NS
Gender, n (%) NS
Male 107 (84.3) 139 (84.2)
Female 20 (15.7) 26 (15.8)
Race/ethnicity, n (%) < 0.001*
White 14 (11.0) 16 (9.9)
Black 60 (47.2) 42 (26.0)
Hispanic/Latino 53 (41.7) 98 (60.5)
Other/unknown 0 (0) 9 (5.5)
HIV risk factor, n (%) NS
Men who have sex with men 39 (30.7) 58 (35.2)
Intravenous drug use 18 (14.2) 14 (8.5)
Heterosexual 36 (28.3) 44 (26.7)
Blood transfusion 1 (0.8) 2 (1.2)
Unknown 33 (26.0) 47 (28.5)
Medical history, n (%)
Initial HIV diagnosis 26 (20.5) 54 (32.7) 0.02
History of PCP 38 (29.9) 34 (20.6) 0.04
Use of PCP prophylaxis 44 (34.6) 48 (29.1)
Use of HAART 57 (44.9) 50 (30.3) 0.02
Current smoker 54 (42.5) 62 (37.6)
Laboratory values NS
CD4, cells/μl, median(range)(n = 131) 27 (0–697) 17 (0–267)
HIV viral level, median log copies/ml (range)(n = 57) 5.1 (2.6–5.9) 5.3 (1.7–5.9)
Albumin, g/dl, median (range) 2.5 (0.6–3.7) 2.4 (1.0–3.8)
LDH, U/l, median (range) 317 (129–851) 362 (119–962)
Alveolar-arterial oxygen gradient, mm Hg, median (range)(n = 129) 41.5 (18.0–89.0) 43.4 (22.3–82.0)
Complications, n (%)
ICU admission 30 (23.6) 70 (42.4) 0.001
Mechanical ventilation 10 (7.9) 29 (17.6) 0.02
Pneumothorax 2 (1.6) 18 (10.9) 0.002
Respiratory failure after 5 days 1 (0.8) 9 (5.5) NS
Change of PCP therapy 1 (0.8) 13 (7.9) 0.005
HAART started in hospital, n (%) 5 (7.7) 11 (10.5) NS
Outcome
Died in-hospital 8 (6.3) 26 (15.8) 0.01
Abbreviations: HAART, highly active antiretroviral therapy; ICU, intensive care unit; LDH, lactate dehydrogenase; NS, not significant; PCP, 
Pneumocystis pneumonia.*For overall comparison. p < 0.001 for blacks compared to Hispanic/Latinos and p = 0.018 for blacks compared to others/
unknown. p-values adjusted for multiple comparisons.Page 5 of 10
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six subjects (34.3%) reported that they were not taking
their HAART regimens as prescribed. Laboratory values of
CD4 cell count, plasma HIV viral levels, serum albumin,
and LDH were comparable in the HAART and non-
HAART groups. There was a trend for subjects on HAART
to be admitted to the ICU less often (27.1% versus 37.1%,
OR = 0.62, 95%CI = 0.37–1.05, p = 0.08) and to require
mechanical ventilation less frequently (10.3% versus
14.0%, OR = 0.70, 95%CI = 0.33–1.49, p = 0.36) than the
non-HAART subjects. Subjects on HAART were signifi-
cantly less likely to develop a pneumothorax (1.9% vs.
9.6%, OR = 0.18, 95%CI = 0.041–0.80, p = 0.01). Length
of stay was also shorter for those receiving HAART at
admission (6 days vs. 9 days, p < 0.001).
Of those receiving HAART, 46 (43.0%) continued using
HAART during admission. Sixteen patients (5.5%) started
HAART during admission. HAART was started a median of
16 days after hospital admission (range 2–66) and a
median of 9 days before discharge (range 2–28). Patients
who continued or started HAART received it for a median
of six days during admission (range 1–21). Approximately
15% of patients had at least one dose held during hospi-
talization. Reasons cited were the need to stop oral intake,
development of side effects, or interaction with other
medications.
Mortality was comparable for those on HAART at hospital
admission and those not on HAART (9.3% vs. 11.8%, p =
0.52). Cox proportional survival modeling did not dem-
onstrate any difference in survival to hospital discharge in
those continued on HAART during hospitalization, those
started on HAART while hospitalized, or these groups
combined.
Discussion and conclusion
This study demonstrated that in-hospital mortality of
HIV-infected patients with PCP admitted to LAC-USC
hospital from 2000 to 2003 was 11.6% and ICU mortality
was 29.0%. The need for mechanical ventilation, develop-
ment of a pneumothorax, and low serum albumin were
found to be independent predictors of mortality. In con-
trast to our previous work [9], use of HAART during
admission did not have an association with mortality.
As seen in previous studies of PCP, the majority of our
patients were not using PCP prophylaxis. Although many
should have been taking PCP prophylaxis based on clini-
cal criteria, we cannot determine from chart review
whether they were non-compliant with prescribed ther-
apy, did not have therapy prescribed by their provider, or
were not in care despite a known diagnosis of HIV infec-
tion. As also seen in previous studies, the admission with
PCP was often the subject's first diagnosis of HIV infec-
tion. PCP diagnoses in HAART users may have repre-
sented failing HAART regimens or non-compliance with
HAART. Immune reconstitution inflammatory syndrome
(IRIS) might also have accounted for some of these diag-
noses, although we were unable to distinguish these pos-
sibilities from chart review [16].
In our study, there were a large number of empirically-
diagnosed patients who differed from those in whom
Table 3: Predictors of in-hospital mortality for HIV-infected patients with Pneumocystis pneumonia for the entire cohort and according 
to empiric or definitive diagnosis.
Univariate predictors All subjects (n = 292) OR 
(95% CI), p-value
Empiric (n = 127) OR 
(95% CI), p-value
Definitive (n = 165) OR 
(95% CI), p-value
Mechanical ventilation 18.0 (7.9–41.1), < 0.001 86.3 (13.1–568.3), <0.001 9.6 (3.8–24.7), < 0.001
Pneumothorax 10.3 (3.9–27.3), < 0.001 _* 10.2 (3.5–29.7), < 0.001
Serum LDH (per 100 U/l increase) 1.3 (1.09–1.65), 0.005 1.3 (0.79–2.02), 0.33 1.3 (1.02–1.63), 0.03
Serum albumin 
(per 0.1 g/dl increase)
0.32 (0.17–0.60), < 0.001 0.27 (0.09–0.88), 0.02 0.36 (0.17–0.77), 0.008
Empiric diagnosis 0.36 (0.16–0.82), 0.02 _ _
Alveolar-arterial oxygen gradient 
(per 1 mm Hg increase)(n = 129)
1.08 (1.03–1.12), 0.001 1.05 (0.98–1.12), p = 0.16 1.10 (1.03–1.17), p = 0.003
Multivariate predictors 
(n = 278)
Pneumothorax 15.7 (4.4–56.4), < 0.001
Mechanical ventilation 14.8 (5.7–38.9), < 0.001
Serum albumin 
(per 0.1 g/dl increase)
0.27 (0.12–0.61), 0.002
Abbreviations: CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio.
*Unable to calculate odds ratio because of the small number of occurrences.Page 6 of 10
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diagnosis were more likely to have known HIV, a past his-
tory of PCP, and to be receiving HAART. Empiric diagno-
sis was associated with improved mortality, but this
association did not persist after adjustment for severity of
illness. Parada and colleagues also found that patients
with an empiric diagnosis of PCP had comparable mortal-
ity to those with definitive diagnoses [17]. In contrast, sev-
eral previous studies have found that empiric diagnosis is
associated with worse mortality than definitive diagnosis.
Bennett and colleagues reported that HIV-infected sub-
jects who had empiric diagnoses of PCP had higher mor-
tality when adjusted for severity of illness [18]. Miller
reported that HIV-infected patients in the ICU with an
empiric diagnosis of PCP had a mortality of 63% com-
pared to 53% for definitive diagnosis, although this differ-
ence was not statistically significant [15]. In our
institution, subjects who are more severely ill, particularly
those who are intubated and in the ICU, are more likely
to undergo bronchoscopy and have a microscopic diagno-
sis which likely explains the mortality differences. How-
ever, because we could not exclude the possibility that
these patients did not in fact have PCP, we performed sep-
arate mortality analyses for definitive and empiric diag-
nostic groups and found similar predictors and therefore
included both groups in our multivariate model. In addi-
tion, because many hospitals do not pursue definitive
diagnosis, we felt that these results would reflect the gen-
eral population of PCP patients.
Interestingly, empirically-diagnosed patients were much
more likely to be black, which was the only characteristic
independently associated with an empiric diagnosis. The
reasons for this are unclear, but studies of the effects of
race on invasive procedures in the non-HIV-infected pop-
ulation have found that blacks are less likely to undergo
bronchoscopy when seriously ill, less likely to have car-
diac catheterization when having an acute myocardial inf-
arction, and less likely to have lung surgery when
diagnosed with lung cancer [19-21]. Other studies have
examined racial differences in PCP and HIV-related care.
Bennett found that black and Hispanic patients with PCP
were less likely to have a bronchoscopy and more likely to
die, but this effect was actually a function of insurance and
hospital characteristics [22]. Others have also found that
HIV-infected patients are less likely to undergo bronchos-
copy if they have Medicaid as opposed to private insur-
ance [17]. We do not have insurance information on our
patients to determine if it accounts for the racial difference
in empiric diagnoses, but LAC-USC is a county hospital
that typically serves patients who are underinsured or
have no insurance. This finding suggests that there may
still be some bias in performing procedures in certain
groups of patients.
Due to the heterogeneity of patient populations, differing
admission standards, influence of decisions to withdraw
care, and variable clinical practices, it is difficult to com-
pare our mortality results to previous studies. Reported
hospital mortality of HIV-infected patients with PCP prior
to HAART ranged from 13% to 25% [23,24]. In the early
HAART era (1995–1997), PCP mortality was 11.3% [7].
We found a similar mortality of 11.6%, suggesting that
overall mortality of PCP has not changed a great deal.
Mortality of PCP patients requiring intensive care ranged
from 60 to 76% in the pre-HAART era, but improved
somewhat in the early HAART era [9,25,26]. A previous
study in San Francisco from 1996 through 2001 demon-
strated a mortality of 55% among patients admitted to the
ICU with PCP compared to 63% seen at the same institu-
tion during the years immediately before HAART [9,26].
Others have found mortality rates ranging from 53 to 62%
in the early years of the HAART era [8,10].
Similar to another study which included the later HAART
years [15], our study demonstrates that ICU mortality has
continued to decrease with the current mortality at 29%.
Increased use of non-invasive ventilation, more wide-
spread use of low tidal volume ventilation, and restriction
of intravenous fluids might have improved mortality as
there have been no significant changes in care of PCP to
account for differences. Our cohort might have been
healthier than those in previous studies, but most patients
had advanced AIDS with low CD4 cell counts. ICU admis-
sion standards might also affect mortality. Our ICU has
no set guidelines for ICU admission and transfer and ini-
tial admission to the ICU is at the discretion of the admit-
ting physician. In fact, a higher percentage of our PCP
patients (34%) were admitted to the ICU compared to
only 16% in the study by Miller and colleagues [15].
Despite the difference in admission rates, our ICU mortal-
ity (29%) was quite similar to theirs (34%).
The predictors of mortality that we identified were con-
sistent with previous studies. Mechanical ventilation,
development of a pneumothorax, and low serum albumin
were associated with a poor outcome. These factors have
all been previously found to predict outcome in patients
with PCP or in those with HIV infection [9,11,13,14,27].
In contrast to some previous studies, ICU admission after
several days of treatment was not associated with
increased mortality [9,13,15,28].
One potential factor that could influence current mortal-
ity is the use of HAART. A previous study demonstrated
that PCP patients who received HAART during their ICU
admission had a mortality rate of only 25% compared to
63% for those who did not [9]. In contrast, Miller
reported low ICU mortality despite the fact that noPage 7 of 10
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sion. These results suggest that improvement in the
HAART era was the result of improvements in ICU care,
but there was no comparison group receiving HAART.
Two other studies have not found a difference in ICU
mortality with and without HAART, but these studies have
not examined those with PCP directly [10,29]. There have
been no prior studies examining HAART in non-ICU
patients with PCP.
The current study adds to previous work by examining a
larger group of patients, by including both patients with
and without HAART use as well as those not requiring ICU
care, and by performing detailed analyses of HAART use.
Overall, there was no significant relationship between
HAART and survival. We found no mortality effect in
patients who started HAART or who had it continued in
the hospital. Our subjects started HAART, on average,
more than two weeks after hospital admission and
received it only for an average of six days, which likely
would not be long enough to see a beneficial effect.
Patients in the previous study reporting a beneficial effect
of HAART might have received it for a longer time or more
quickly after hospital admission than the current patients,
but these data were not collected [9]. Other explanations
of the inconsistent results are differences in patient popu-
lations or that improvements in ICU care of PCP patients
have had a greater impact on mortality than the effects of
HAART. There are significant risks associated with initiat-
ing HAART in the acute setting including difficulties with
administration and absorption that could lead to resist-
ance, drug toxicities and interactions, and the develop-
ment of IRIS. Given the low numbers of subjects receiving
HAART in this study and the many factors that can affect
both the clinical decision and the ability to start HAART
in the hospital, our results need to be interpreted with
caution, but they do not suggest a benefit from HAART in
this setting.
Another area of controversy has been whether patients
receiving HAART present differently from those not
receiving HAART at admission. Although HAART patients
generally had similar serum albumin and LDH levels, they
were less likely to have a pneumothorax and tended to be
less likely to require mechanical ventilation or ICU admis-
sion and thus seemed to have had less severe illness. This
finding might be due to a tendency for subjects who were
in care and with known HIV status to seek medical atten-
tion at an earlier point in the disease or there might be
some differences in the presentation of the disease in
HAART users. In addition, HAART use prior to admission
was associated with a shorter length of stay, possibly
reflecting more stable housing situations or perhaps indi-
cating a beneficial effect of HAART separate from any
effects on mortality. Patients who reported using HAART
at admission did not actually have lower HIV viral RNA
levels than those not on HAART. There are several poten-
tial explanations of the detectable viral levels in these
patients. First, they may not have been compliant with the
regimens as approximately one-third of subjects reported
not taking their medications as prescribed. Also, of the
subjects in whom length of HAART use was known, many
had recently started HAART and might not have had suffi-
cient time to see benefit. Finally, HAART might not have
been effective in these selected patients as those with suc-
cessful HAART use would not be expected to develop PCP.
There are several limitations of this study. First, it is retro-
spective and from a single center. Different populations or
different hospitals could be expected to have different
results. Factors such as criteria for ICU admission and
views of limitations of care could influence outcomes.
Another difficulty is that our analysis of the effects of
HAART on mortality might be altered by the fact that
patients selected to start HAART either before or during
admission may differ from those not interested in or not
offered the therapy. Also, pre-hospital data regarding
markers of HIV infection and prognosis were not available
for a number of subjects, limiting our ability to analyze
the effect of these factors on in-hospital outcome. Finally,
we might have lacked sufficient power to detect a differ-
ence in subjects on HAART. Larger, prospective studies
would be needed to determine the effects of initiating
HAART during hospitalization for acute PCP.
In summary, overall hospital mortality for PCP is similar
to that reported earlier in the HAART era, but ICU mortal-
ity appears to be lower than that previously reported at
other centers. Whether current ICU mortality represents
improvements in general ICU care or changes in the HIV-
infected population is unknown, but should provide cli-
nicians with justification and optimism for continued
ICU care of these patients. Predictors of mortality have not
changed in the recent HAART era and need for mechanical
ventilation, development of a pneumothorax, and low
serum albumin still portend a poor outcome. PCP diag-
noses in HAART users likely represented failing HAART
regimens or non-compliance with HAART. Administra-
tion of HAART during hospitalization or continuation of
a potentially failing HAART regimen was not associated
with a decrease in mortality, but larger, prospective stud-
ies are needed to confirm the true relationship of HAART
to outcome of PCP.
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